Glaukos Co. (NYSE:GKOS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Glaukos Co. (NYSE:GKOS - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $99.80.

GKOS has been the subject of a number of analyst reports. Needham & Company LLC upped their price target on Glaukos from $105.00 to $108.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. Stifel Nicolaus reiterated a "buy" rating and issued a $110.00 price objective on shares of Glaukos in a research report on Wednesday, April 3rd. Citigroup upped their price target on Glaukos from $107.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, March 25th. StockNews.com cut Glaukos from a "hold" rating to a "sell" rating in a research note on Tuesday, February 27th. Finally, JPMorgan Chase & Co. upgraded Glaukos from a "neutral" rating to an "overweight" rating and raised their price target for the company from $66.00 to $91.00 in a research note on Thursday, December 21st.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,372 shares of the firm's stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $100.54, for a total transaction of $137,940.88. Following the transaction, the chief financial officer now owns 52,532 shares of the company's stock, valued at $5,281,567.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Glaukos news, CFO Alex R. Thurman sold 1,372 shares of the business's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $100.54, for a total transaction of $137,940.88. Following the transaction, the chief financial officer now owns 52,532 shares in the company, valued at approximately $5,281,567.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark J. Foley sold 4,560 shares of the business's stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $92.87, for a total value of $423,487.20. Following the transaction, the director now owns 33,220 shares in the company, valued at approximately $3,085,141.40. The disclosure for this sale can be found here. Insiders have sold a total of 242,881 shares of company stock valued at $22,906,633 over the last quarter. 7.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Glaukos

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Glaukos by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 5,380,720 shares of the medical instruments supplier's stock worth $286,470,000 after acquiring an additional 23,473 shares in the last quarter. Brown Capital Management LLC lifted its stake in Glaukos by 3.4% in the 4th quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier's stock valued at $214,448,000 after buying an additional 89,420 shares in the last quarter. Braidwell LP lifted its stake in Glaukos by 8.7% in the 1st quarter. Braidwell LP now owns 1,806,651 shares of the medical instruments supplier's stock valued at $90,513,000 after buying an additional 144,800 shares in the last quarter. State Street Corp lifted its stake in Glaukos by 1.8% in the 2nd quarter. State Street Corp now owns 1,782,347 shares of the medical instruments supplier's stock valued at $126,921,000 after buying an additional 31,471 shares in the last quarter. Finally, Fred Alger Management LLC lifted its stake in Glaukos by 9.2% in the 3rd quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier's stock valued at $133,997,000 after buying an additional 150,102 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

Shares of GKOS stock traded up $1.27 on Friday, hitting $96.40. The company had a trading volume of 697,810 shares, compared to its average volume of 674,916. The firm has a market cap of $4.84 billion, a P/E ratio of -34.68 and a beta of 1.08. Glaukos has a twelve month low of $45.38 and a twelve month high of $102.33. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77. The company has a 50-day moving average price of $91.88 and a 200-day moving average price of $80.73.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.07). The business had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The business's revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.53) EPS. As a group, equities research analysts predict that Glaukos will post -2.18 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.